Conestoga Capital Asesoresan asset management company, published its Q1 2026 investor letter. A copy of the letter can be downloaded here. The first quarter of 2026 began with optimism about the domestic economy and attractive small-cap valuations, but was affected by volatility stemming from geopolitical unrest in the Middle East and changing interest rate expectations. This unrest drove up energy prices and created cautious global markets. Energy, Basic Materials and Industrials performed well, while software companies faced challenges due to concerns about AI disruption. Market sensitivity to geopolitical developments, energy prices and inflation remains high. The Conestoga Small Cap Composite fell 5.01%, underperforming the Russell 2000 Growth’s -2.81% return. The decline was driven by negative stock selection and difficulties in Technology and Healthcare, with sector allocation gains insufficient to offset losses. Plus, check out the strategy’s top five holdings for your best picks in 2026.
In its Q1 2026 investor letter, Conestoga Capital Advisors highlighted stocks like Stevanato Group SpA (NYSE:STVN). Stevanato Group SpA (NYSE:STVN) is an Italian company that designs and distributes products and processes to offer integrated solutions for the biopharmaceutical and healthcare industries. On April 24, 2026, Stevanato Group SpA (NYSE:STVN) closed at $16.18 per share. Stevanato Group SpA (NYSE:STVN)’s monthly return was 20.12% and its stock lost 25.02% in the last 52 weeks. Stevanato Group SpA (NYSE:STVN) has a market capitalization of approximately $4.42 billion.
Conestoga Capital Advisors stated the following regarding Stevanato Group SpA (NYSE:STVN) in its Q1 2026 investor letter:
“Stevanato Group SpA (NYSE:STVN) provides drug containment and delivery solutions to pharmaceutical and biotechnology companies. The stock struggled as investors weighed strong results against a mixed underlying business mix and moderate growth profile. While margins improved and high-value solutions continued to scale, overall revenue growth remained relatively modest at 5% in the quarter. Continued weakness in the Engineering segment and a shift toward higher value products contributed to a more muted market reaction. The stock is also pressured by the decline in oral GLP-1 versus GLP-1.”
Stevanato Group SpA (NYSE:STVN) isn’t on our list of the 40 most popular stocks among hedge funds heading into 2026. According to our database, 15 hedge fund portfolios held Stevanato Group SpA (NYSE:STVN) at the end of the fourth quarter, up from 13 in the prior quarter. In Q4 2025, Stevanato Group SpA (NYSE:STVN) revenue grew 7% at constant exchange rates and 5% on a reported basis to $346.5 million. While we recognize the potential of Stevanato Group SpA (NYSE:STVN) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that’s also benefiting significantly from Trump-era tariffs and the offshoring trend, check out our free report on best short-term AI stock.